Johnson & Johnson (JNJ) shares advanced Tuesday after the pharmaceutical and medical device company posted bet𒀰ter third-qua🤡rter sales and adjusted profit than expected.

Johnson & Johnson reported $22.47 billion in revenue, up 5% year-over-year and better than 澳洲幸运5官方开奖结果体彩网:analysts had projected, according to estimates compiled by Visible Alpha. It registered $2.69 billion in 澳洲幸运5官方开奖结果体彩网:net income, down 38% and well short of expectation, on billions in one-time expenses like legal costs and 澳洲幸运5官方开奖结果体彩网:acquisitions.

Adjusted Profit Beats Estimates

After accounting for over $3 billion in one-time 澳洲幸运5官方开奖结果体彩网:expenses like legal costs, "intangible 澳洲幸运5官方开奖结果体彩网:asset amortization expense," 🐷and the cost of acquisitions, Johnson & Johnso💛n's adjusted profit of $5.88 billion came in more than half a billion dollars higher than expected.

The company also adjusted its 澳洲幸运5官方开奖结果体彩网:full-year outlook, lifting sales projections to $88.4 billion to $88.8 billion from the prior range of $88 billion to $88.4 billion. Still, Johnson & Johnson lowered its adjusted 澳洲幸运5官方开奖结果体彩网:earnings per share (EPS) projections to $9.88 per share to $9.98 per share from $9.97 to $10.07 to account for the impact of its recently completed acquisition of V-Wave, which develops 澳洲幸运5官方开奖结果体彩网:treatments for heart failure.

澳洲幸运5官方开奖结果体彩网:Chief Executive Officer (CEO) Joaquin Duato said the company's recent drug approvals and development milestones o♌f other projects is "further strengthening our confidence in our near- and long-term growth targets."

Johnson & Johnson shares fell in premarket trading after the report but were up 2% in late-morning ♉trading. They are about 5% higher this year.

UPDATE—This story has been updated with the la😼test share price information.